Therapeutic Advances in Rare Disease
Journal Highlights
- Launched in 2020
- Gold open access journal – all articles are made freely available online immediately upon publication
- Rigorous peer review
- Free to publish in for an introductory period
- Reaches a broad, multidisciplinary audience
Therapeutic Advances in Rare Disease (TAIRD) is a peer-reviewed open access journal which focuses on the highest quality research, reviews and scholarly comment on pioneering efforts and innovative studies across all rare diseases. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers, providing an online forum for publishing the highest quality articles in this area. Please see the Aims and Scope tab for further information.
Diversity, Equity and Inclusion StatementTherapeutic Advances in Rare Disease (TAIRD) promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the rare disease community.
Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.
We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socioeconomic status or any other individual status.
We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.
Submission information
Submit your manuscript today at http://mc.manuscriptcentral.com/taird.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access information
This journal does not currently charge an article processing charge (APC) for open access publication. The article processing charge for a Plain Language Summary of Publication is $4500.
Contact
Please direct any queries to TARareDisease@sagepub.com.
Therapeutic Advances in Rare Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on the diagnosis and medical treatment of rare diseases and orphan drugs. The journal has a strong research and clinical focus and is aimed at clinicians, researchers in both academia and healthcare industries, as well as manufacturers through to policy-makers, providing an online forum for publishing the highest quality articles in this area.
The editors welcome original research articles across all areas of rare disease including:
· Clinical genetics and genomics
· Dysmorphology
· Ethical and legal perspectives
· Inherited metabolic diseases
· Lysosomal storage diseases
· Mitochondrial Diseases
· Orphan Drugs
· Rare bone diseases and skeletal dysplasias
· Rare cardiovascular diseases
· Rare coagulation diseases
· Rare endocrinological diseases
· Rare gastrointestinal diseases
· Rare immune deficiencies
· Rare infectious diseases
· Rare kidney diseases
· Rare neurological diseases
· Rare ophthalmological diseases
· Rare respiratory diseases
· Rare skin diseases
· Rare tumors
· Regulatory, reimbursement and government policy
Therapeutic Advances in Rare Disease conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be follows (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses).
| Tiina Urv PhD | Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, USA |
| Samantha Taylor | SAGE Publishing, London, UK |
| Suvra Moulick | SAGE Publishing, New Delhi, India |
| Claudia A. Chiriboga MD, MPH | Columbia University Irving Medical Center, New York, USA |
| Alice Chen Grady MD | Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, NIH, Bethesda, USA |
| Larissa Kerecuk MBBS, BSc | Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK |
| Jemima Mellerio MD | St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK |
| Katrin Õunap MD, PhD | University of Tartu and Tartu University Hospital, Tartu, Estonia |
| Maurizio Scarpa MD, PhD | Center for Rare Diseases, Udine University Hospital, Udine, Italy |
| Marcela Votruba BM BCh, BA, MA | Vision Sciences, Cardiff University, UK |
| Annemieke Aartsma-Rus PhD | Leiden University Medical Center, Leiden, The Netherlands |
| Dionysios Alexandrou MD MD Res | Moorfields Hospital NHS Trust, London, UK |
| Guilherme Baldo PharmD PhD | Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil |
| John Bladen BSc PhD | Kings College Hospital NHS Foundation Trust, London, UK |
| Roberto Giugliani MD PhD MSc | Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil |
| Andrea Gropman, MD | Children's National Medical Center, Children's Research Institute, Washington DC, USA |
| Jeanine Jarnes PharmD BCOP BCPS | University of Minnesota, MN, USA |
| Mariya Moosajee BSc PhD | University College London, London, UK |
| Mukund Nori BSc MSc PhD | rareLife solutions, South Norwalk, CT, USA |
| Daniele Orsucci MD | Unit of Neurology, San Luca Hospital, Lucca, Italy |
| Arrigo Schieppati MD PhD | Rare Disease Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy |
| Willeke van Roon-Mom PhD | Leiden University Medical Center, Leiden, The Netherlands |
| Jasmin Barman-Aksözen | International Porphyria Patient Network, Zurich, Switzerland |
| Daniel O’Reilly | RNA Therapeutics Institute, UMass Medical School, MA, USA |
| Simon Stones | Collaboro Consulting, Manchester, UK |
| Russell Wheeler | Leber's Hereditary Optic Neuropathy Society, UK |
| Laurence Woollard | On The Pulse Consultancy Ltd, Cambridge, UK |
| Ariadna Bargiela PhD | University of Valencia, Valencia, Spain |
| Marc Micó-Carnero BSc, MSc | August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain |
| Annalisa Sechi MD, PhD | Regional Coordinating Centre for Rare Diseases, University Hospital of Udine, Udine, Italy |
| Kuntal Sen MD, FACMG | Children’s National Hospital, Washington, D.C., USA |
- PubMed Central (PMC)
- Scopus
Manuscript submission guidelines can be accessed on Sage Journals.